Abstracts Archive - Page 1752 of 2425 - ACR Meeting Abstracts

Abstract Number: 940 • 2015 ACR/ARHP Annual Meeting
NOD2-Associated Autoinflammatory Disease: Therapy and Outcomes
Qingping Yao¹ and Bo Shen², ¹Cleveland Clinic, Cleveland, OH, ²Gastroenterology, Cleveland Clinic, Cleveland, OH
Background/Purpose: NOD2-associated autoinflammatory disease, now redesignated as Yao Syndrome(YS) is a newly described and increasingly recognized entity. It is characterized by periodic fever, dermatitis, polyarthritis, sicca-like…
Abstract Number: 941 • 2015 ACR/ARHP Annual Meeting
Relationship Between Colchine Plasma Level and Frequency of Familial Mediterranean Fever Attacks
Fadime Canbolat¹, Gulsen Ozen², Selma Ozilhan¹, Samet Gulturk³, Ayse Ozcetin⁴, Ali Ugur Unal², Nevsun Inanc², Pamir Atagunduz², Haner Direskeneli² and Tuncel Ozden¹, ¹Department of Pharmacology, Uskudar University Pharmacogenetic Laboratory, Istanbul, Turkey, ²Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Molecular Biology and Genetics, Uskudar University, Istanbul, Turkey, ⁴Department of Neuroscience, Uskudar University, Istanbul, Turkey
Background/Purpose: Colchicine is the mainstay of Familial Mediterranean Fever (FMF) treatment that reduces the frequency of attacks and prevents amyloidosis in the majority of patients. Colchicine,…
Abstract Number: 942 • 2015 ACR/ARHP Annual Meeting
Update in the Management of Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs Following Coccidioidomycosis
Usman Ajaz¹, Neil M. Ampel², Varun Bhalla³, Jeffrey R. Lisse⁴ and Dominick Sudano⁵, ¹Department of Medicine, University of Arizona, Tucson, AZ, ²Department of Infectious Disease, Southern AZ VA Medical Center, Tucson, AZ, ³University of Arizona, Tucson, AZ, ⁴Arizona Arthritis Center, University of Arizona, Tucson, AZ, ⁵Rheumatology, University of Arizona, Tucson, AZ
Background/Purpose: In the Southwestern United States, Coccidioidomycosis (cocci) or Valley fever is an endemic fungal infection. It typically presents as a self-limited pulmonary illness. Patients…
Abstract Number: 943 • 2015 ACR/ARHP Annual Meeting
Development of an Internationally Agreed Minimal Dataset for Juvenile Dermatomyositis (JDM) for Clinical and Research Use
Liza J. McCann¹, Lucy R Wedderburn², Clarissa Pilkington³, Adam M. Huber⁴, Angelo Ravelli⁵, Jamie Kirkham⁶, Paula Williamson⁶ and Michael W. Beresford⁷, ¹Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ³Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁴Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁵Pediatria-II, IRCCS G. Gaslini and University of Genova, Genova, Italy, ⁶Department of Biostatistics, University of Liverpool, MRC North West Hub for Trials Methodology Research, Liverpool, United Kingdom, ⁷Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare disease. International collaboration is essential for scrutiny of sufficient patient numbers. We aim to develop a core set…
Abstract Number: 944 • 2015 ACR/ARHP Annual Meeting
Activity of Type I and Type II Interferons in Dermatomyositis Skin Is Correlated with Characteristic Pathologic Features
Hayley W. Leatham¹, Kerri Rieger², Lorinda Chung³, Shufeng Li¹, Brandon W. Higgs⁴, Yihong Yao⁴, Kavita Sarin¹ and David Fiorentino¹, ¹Dermatology, Stanford University, Stanford, CA, ²Dermatopathology, Stanford University, Stanford, CA, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose :Interferon (IFN) signaling is upregulated in dermatomyositis (DM) skin, but the relationship to classic histopathologic features is unknown. Methods :Thirty-nine skin biopsies from patients…
Abstract Number: 945 • 2015 ACR/ARHP Annual Meeting
Anti-Hmgcr Antibodies As Specific Marker for Immune Mediated Necrotizing Myopathies
Lucile Musset¹, Chelsea Bentow², Marvin J. Fritzler³, Jiri Vencovsky⁴, Olivier Benveniste⁵, Ignacio Garcia de la Torre⁶, Franco Franceschini⁷, Katalin Danko⁸, Qinglin Peng⁹, Sophie Hue¹⁰, Olivier Boyer¹¹, Nicola Bizzaro¹², Yoshinao Muro¹³, Xavier Bossuyt¹⁴, Anna Ghirardello¹⁵ and Michael Mahler¹⁶, ¹Immunology, Immunochemistry & Autoimmunity Laboratory, Pitié-Salpêtrière University Hospital, Paris, France, ²Research, Inova Diagnostics, San Diego, CA, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute of Rheumatology, Charles University, Prague, Czech Republic, ⁵Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁶Hospital General de Occidente, Zapopan, Mexico, ⁷Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁸Division of Clinical Immunology, 3rd Department of Internal Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary, Co-Author, Debrecen, Hungary, ⁹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ¹⁰CHU Henri Mondor, APHP, Créteil, France, ¹¹Immunology, INSERM, U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, Rouen, France, ¹²Laboratory of Clinical Pathology, San Antonio Hospital, Tolmezzo, Italy, ¹³Dermatology, Division of Connective Tissue Disease & Autoimmunity, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹⁴Laboratory Medicine, University Hospitals Leuven, and Department of Microbiology and Immunology, Catholic University of Leuven, Leuven, Belgium, ¹⁵Department of Medicine-DIMED, University of Padova, Padova, Italy, ¹⁶Inova Diagnostics, San Diego, CA
Background/Purpose :Autoantibodies are important biomarkers in the diagnosis of idiopathic inflammatory myopathies (IIM) including polymyositis (PM) and dermatomyositis (DM), inclusion body myositis (IBM) as well…
Abstract Number: 946 • 2015 ACR/ARHP Annual Meeting
Novel Tripartite Motif Proteins Linked to Membrane Integrity As Biomarkers of Dermatomyositis and Polymyositis
Kevin McElhanon¹, Jenna Alloush¹, Nicholas A. Young², Zarife Sahenk³, Rohit Aggarwal⁴, Chester V. Oddis⁵, Wael N. Jarjour² and Noah Weisleder¹, ¹Department of Physiology and Cell Biology, Davis Heart and Lung Research Institute, The Ohio State University College of Medicine, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Neurology, Research Institute at Nationwide Children's Hospital, Columbus, OH, ⁴Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The mechanisms that contribute to the pathogenesis of the idiopathic inflammatory myopathies remains largely unknown. This heterogeneous group of diseases involve autoimmunity toward muscles…
Abstract Number: 947 • 2015 ACR/ARHP Annual Meeting
Cohesin Complex Is a New Myositis Autoantigen
Shin Tanaka¹, S. John Calise², Yurie Satoh³, Yoshiya Tanaka⁴, Monica Vazquez-Del Mercado⁵, Gabriel Medrano-Ramírez⁶, Eric S. Sobel⁷, Westley H. Reeves⁸, Edward K.L. Chan⁹ and Minoru Satoh¹⁰, ¹Human, Information and Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Department of Oral Biology, University of Florida, Miami, FL, ³First Department of Internal Medicine, University of Occupational and Environmental Health, KItakyushu, Japan, ⁴The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan, ⁵Servicio de Reumatología, División de Medicina Interna, Hospital Civil Dr. Juan I. Menchaca, Guadalajara, Mexico, ⁶Rheumatology, Hospital General de Mexico, Secretaria de Salud, Mexico City, Mexico, ⁷Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁸Medicine, University of Florida, Gainesville, FL, ⁹Dept of Oral Biology, University of Florida, Gainesville, FL, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Each myositis specific autoantibodies (MSA) are associated with unique clinical subset and useful biomarkers in polymyositis/dermatomyositis (PM/DM). Identifying new MSA will help in monitoring…
Abstract Number: 948 • 2015 ACR/ARHP Annual Meeting
Autoimmune Myopathies: Effects of Intravenous Immunoglobulin Therapy on Muscle Strength and Predictors of Response
Arash Lahoutiharahdashti¹, Iago Pinal-Fernandez², Jemima Albayda¹, Julie J. Paik³, Sonye K. Danoff⁴, Andrew Mammen⁵ and Lisa Christopher-Stine⁶, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Autoimmune Systemic Diseases Unit, Vall D’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: There is a variable response rate to Intravenous immunoglobulin (IVIG) in patients with autoimmune myopathies. The aim of this study was to determine whether…
Abstract Number: 949 • 2015 ACR/ARHP Annual Meeting
The Metabolic Syndrome, Its Elements and Knee Osteoarthritis: The Framingham Osteoarthritis (OA) Study
Jingbo Niu¹, Mary Clancy², Piran Aliabadi³ and David T. Felson¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology, BUSM, Boston, MA, ³Radiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recent studies have suggested an association between knee OA and the metabolic syndrome (MetS), but in these studies the relationship of this syndrome to…
Abstract Number: 950 • 2015 ACR/ARHP Annual Meeting
In a Two-Year Double-Blind Randomized Controlled Multicenter Study, Chondroitin Sulfate Was Significantly Superior to Celecoxib at Reducing Cartilage Loss with Similar Efficacy at Reducing Disease Symptoms in Knee Osteoarthritis Patients
Jean-Pierre Pelletier¹, Jean Pierre Raynauld², André Beaulieu³, Louis Bessette⁴, Frédéric Morin⁵, Artur J Fernandes⁶, François Abram⁷, Marc Dorais⁸ and Johanne Martel-Pelletier⁹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Osteoarthritis Research Unit, CRCHUM, Montreal, Montreal, QC, Canada, ³Centre de rhumatologie St-Louis, St. Louis, QC, Canada, ⁴Groupe de Recherche en Rhumatologie et Maladies Osseuses, Quebec, Quebec, QC, Canada, ⁵Centre de Recherche Musculo-squelettique, Trois-Rivières, Trois-Rivières, QC, Canada, ⁶Centre de Recherche Musculo-squelettique, Trois-Rivières, 6Rheumatology Division, Sherbrooke, Sherbrooke, QC, Canada, ⁷Medical Imaging Research & Development, ArthroLab Inc, Montreal, QC, Canada, ⁸StatSciences Inc., Montreal, Canada, Montreal, QC, Canada, ⁹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM),, Montreal, QC, Canada
Background/Purpose: In osteoarthritis (OA) treatment, although chondroitin sulfate (CS) was found in a number of studies using radiography to have a structure modifying effect, to…
Abstract Number: 951 • 2015 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tai Chi Versus Physical Therapy in Treating Knee Osteoarthritis: A Randomized, Single-Blind Trial
Chenchen Wang^1,2, Christopher Schmid³, Maura D. Iversen⁴, William F. Harvey², Roger A. Fielding⁵, Jeffrey B. Driban², Lori Lyn Price⁶, John B. Wong^7,8, Kieran Reid⁵, Ramel Rones⁹ and Timothy E. McAlindon², ¹Rheumatology, Tufts Medical Center, Bosotn, MA, ²Rheumatology, Tufts Medical Center, Boston, MA, ³Brown University School of Public Health, Providence, RI, ⁴Northeastern University,, Boston, MA, ⁵Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, ⁶Clinical Care Research, Tufts Medical Center, Boston, MA, ⁷Tufts Medical Center, Boston, MA, ⁸Clinical Decision Making, Tufts Medical Center, Boston, MA, ⁹Center for Mind–Body Therapies, Boston, MA
Background/Purpose: Knee osteoarthritis (OA) causes long-term pain and no effective treatments currently exist. Previous trials demonstrated that Tai Chi can improve both physical and mental…
Abstract Number: 952 • 2015 ACR/ARHP Annual Meeting
Cost-Effectiveness of Opioids for the Treatment of Knee Osteoarthritis: Impact of Chronic Opioid Use on Total Knee Arthroplasty Outcomes
Savannah R. Smith¹, Jeffrey N. Katz², Jamie E. Collins³ and Elena Losina⁴, ¹Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Orthopedics, Brigham and Women's Hospital, BU School of Public Health and Harvard Medical School, Boston, MA
Background/Purpose: The US spends over $1 billion annually on opioids for persons with knee OA. We evaluated whether the use of opioids offers good value…
Abstract Number: 953 • 2015 ACR/ARHP Annual Meeting
Effectiveness of a Progressive Resistence Strength Programme on Hand Osteoarthritis: A Randomized Crontrolled Trial
Michele V. Nery¹, Anamaria Martinez², Fabio Jennings³, Marcelo Souza² and Jamil Natour², ¹Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Federal University of Sao Paulo, Sao Paulo, Brazil, ³Disciplina de reumatologia, Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: Hand osteoarthritis (OA) is highly prevalent, affecting 55-70% of the population over 55 years with an age-related progressive increase. The OA of interphalangeal (IF)…
Abstract Number: 954 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Osteoarthritis and Cardiovascular Disease: Results from a Population-Based Cohort
Lauren King¹, Tetyana Kendzerska^1,2,3 and Gillian Hawker^1,2,3, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
Background/Purpose: Symptomatic osteoarthritis (OA) and cardiovascular disease (CVD) commonly co-exist. Our aim was to determine the extent to which this relationship is explained by common…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].